Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Discover
Back to filter
Show all topics (10)
Related topics
Intoducing cellenONE: The revolutionary Single Cell isolator
May 25, 2022
A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
May 4, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Molecular imaging study design basics
Jan 31, 2022
By combining study design, study management, and image analytics in all major imaging modalities, BioLaurus has...
Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer
Nov 29, 2021
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
Accelerating AML Research Through Single-cell Multi-omics- integrate seamlessly into existing NGS
Nov 25, 2021
Dr. Linde Miles Memorial Sloan Kettering Cancer Center about her research, use of the Tapestri as a single-cell...
Differentation displacement in acute myeloid leukemia through enhancer activation
Aug 7, 2018
LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.
New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.
Related technologies: Conventional flow cytometry
Brand profile
